Tag Archives: HIV

Medicines Patent Pool: Industry's Toe Still in the Water

At a time when Big Pharma is struggling with new business models geared to the demands of a changing marketplace, the Medicines Patent Pool (MPP) is offering a way forward through voluntary licensing and patent deals that it insists will deliver what the drug majors say they want: more innovation; better market access; and the [...]
Posted in IP, healthcare | Also tagged , , , | Leave a comment

Challenges in the March Toward an AIDS-Free Generation

FDA’s approval of Truvada, a once-a-day oral combination of tenofovir and emtricitabine, for pre-exposure prophylaxis (or PrEP, a method for preventing HIV infection) arrived during a chorus of optimism surrounding major developments in the fight against AIDS.
Posted in Biotech, Events, FDA, Market Access, Patient Communication, Regulatory, Safety, healthcare, patient compliance, patient education, pricing | Also tagged , , , , , , | Leave a comment

HIV Market Banking on Fixed-Dose Treatments

The HIV markets are expected to grow for the next two years, but major patent expirations in the following years will have a huge impact on pharmaceutical sales by 2019, according to a new report by DataMonitor. Antiretroviral sales in 2009 were estimated at $11.8 billion. While that figure is forecast to hit $14.4 billion in [...]
Posted in R&D | Also tagged , , , , , , | Leave a comment

TB Alliance Trumpets New, Improved Drugs at World Health Assembly

Like polio and leprosy, developed countries have long since tamed tuberculosis. But even now, other parts of the world continue to struggle against the disease, with nearly all (98 percent) of TB’s 1.7 million worldwide deaths occurring in developing countries. TB’s high comorbidity with HIV infections has recently added another level of urgency to efforts [...]
Posted in Corporate Responsibility, Emerging Markets, Global, R&D | Also tagged , , , , , , , , , | Leave a comment

Gilead Making a Bundle

Gilead Sciences has once again proven that independent biotechs can innovate with the best of Big Pharma. The Silicon Valley company’s wizardry at weaving multiple drugs into a single weft enabled it to overthrow GlaxoSmithKline as king of HIV in 2007. Yesterday, at the 16th annual Congress of Retroviruses and Opportunistic Infections (CROI), the biotech [...]
Posted in Biotech, Emerging Markets, R&D | Also tagged , , | Leave a comment